5 Results for "

Receptor-ligand interaction

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "Receptor-ligand interaction" in MCE Product Catalog:

Cat. No.: HY-120510
CAS No.: 1206876-95-0
Synonyms: PF 4308515
PF-04308515 is a glucocorticoid receptor ligand. PF-04308515 inhibits IL-6, IFNγ production. PF-04308515 induces weak PGC1α interaction. PF-04308515 has antiinflammatory activities .
loading...
    loading...
Cat. No.: HY-147810
CAS No.: 2758571-64-9
Target:  

5-HT Receptor

Research Areas:  

Neurological Disease

5-HT7 receptor ligand 1 (Compound 5c) is a 5-HT7 receptor ligand with a Ki of 8 nM. 5-HT7 receptor ligand 1 is not hepatotoxic and exhibit moderate potential interaction with other agents metabolized by CYP3A4 or CYP2D6 .
loading...
    loading...
Cat. No.: HY-123661
CAS No.: 1627580-82-8
Target:  

Endogenous Metabolite

Research Areas:  

Neurological Disease

MIPS1455 is a light-activated M1 muscarinic acetylcholine receptor ligand with irreversible binding activity to the allosteric site of the receptor. MIPS1455 is a drug target under investigation for the suppression of cognitive deficits and may become a valuable molecular tool for further investigation of allosteric interactions of the receptor .
loading...
    loading...
Cat. No.: HY-183927
CAS No.: 125141-02-8
Target:  

Dopamine Receptor

Research Areas:  

Neurological Disease

Spectramide is a blood-brain barrier-permeable, reversible, and selective dopamine D2 receptor ligand. Spectramide shows no strong interactions with dopamine D1 receptors, dopamine uptake sites, adrenergic receptor systems, cholinergic receptor systems, or 5-HTR systems. Spectramide can be labeled with 11C or 123I isotopes for use in PET or SPECT. Spectramide preferentially accumulates in the striatum with low uptake in other brain regions, and its accumulation can be blocked by pre-administration of Haloperidol (HY-14538) .
loading...
    loading...
Cat. No.: HY-189454
Target:  

GABA Receptor

Research Areas:  

Neurological Disease

ETK-III-9 is an orally active and blood-brain barrier-penetrant GABAA receptor ligand. ETK-III-9 displaces 3H-flunitrazepam at the benzodiazepine site of GABAA receptors, with stronger interactions at α3β3γ2 and α5β3γ2 subtypes. ETK-III-9 exhibits a target IC50 value of 97.8 nM for rat α3/α5-containing GABAA receptors and 7.6 nM for rat α5β3γ2 subtypes. ETK-III-9 is used in anxiety research .
loading...
    loading...